Major breakthrough in Moderna(MRNA.US) mRNA cancer vaccine ignites market sentiment! The biotech sector revaluation may have just begun
Moderna's phase 3 clinical trial for melanoma has yielded positive results, serving as a catalyst for the entire biotech sector and driving widespread gains in biotech ETFs. This also reignited market confidence in next-generation therapeutic technologies.
According to Zhitong Finance APP, the biotechnology industry is largely driven by clinical events—a successful or failed Phase III clinical trial can cause significant fluctuations in the stock prices of companies directly involved and may also affect the entire therapeutic technology category they represent. When a novel therapeutic technique passes a pivotal clinical trial, the perceived risk for projects using similar methods throughout the R&D pipeline is also reduced accordingly.
mRNA-based cancer therapies are currently one of the most closely watched directions in oncology R&D. Unlike traditional treatments, personalized neoantigen therapy aims to train a patient's immune system to recognize and attack tumors specific to that individual. A successful late-stage clinical trial in this field will have an impact far beyond the companies participating in the trial, influencing gene editing, genomics, and AI-driven drug discovery platforms, as these fields share a broader R&D logic focused on cures.
Last Wednesday, Moderna (MRNA.US) and Merck (MRK.US) announced that the personalized mRNA neoantigen therapy intismeran autogene, in combination with Keytruda, met its primary endpoint in the Phase III INTerpath-001 melanoma clinical trial. This news drove Moderna's stock up by nearly 177% and Merck's by more than 12%. The SPDR S&P Biotech ETF (XBI.US) also rose by nearly 6%, reaching its highest level since February 2021.
The success of this trial also led to widespread gains among companies involved in gene editing and AI drug discovery, with Prime Medicine (PRME.US), Intellia (NTLA.US), CRISPR Therapeutics (CRSP.US), Editas Medicine (EDIT.US), and Beam Therapeutics (BEAM.US) all rising with the broader sector; iShares Genomics Immunology and Healthcare ETF (IDNA.US) surged 13.53% in a single trading day, with trading volume reaching 2.8 times the average.
According to the Bank of America Research Investment Committee, since June, the biotechnology sector's returns have been around 10% or higher. The committee also viewed biotech as a diversified investment direction to avoid crowded positions in tech stocks, ranking alongside insurance companies and regional banks.
Notable Investment Targets
For this theme, the most direct public market investment tools are ETFs focused on the biotech sector. The SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF (IBB.US) provide broad exposure to the industry. The iShares Genomics Immunology and Healthcare ETF is more concentrated in genomics and precision medicine, while the Invesco Biotechnology & Genome ETF (PBE.US) covers both biotechnology and genomics companies.
Recently, besides the directly involved stocks Moderna and Merck, gene editing and rare disease companies that have risen with improved sector sentiment include Prime Medicine, Intellia, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics. AI-driven drug discovery companies Absci (ABSI.US) and Recursion Pharmaceuticals (RXRX.US) have also shown active performance, and Twist Bioscience (TWST.US) is likewise being closely watched.
Analyst Perspectives
Following the announcement of the melanoma clinical trial results, analysts' sentiment towards biotech ETFs shifted notably. The bullish case is focused primarily on valuations, technical momentum, and merger & acquisition potential. At the same time, analysts noted major risks including the macroeconomic environment as well as the high volatility typical of small-cap and clinical-stage companies.
Potential Upside Factors Worth Watching
Valuation gaps may narrow—Financial Serenity estimates that if IDNA's forward valuation multiples move closer to XBI, a one-off re-rating could theoretically drive IDNA's price up about 29.5%. This estimate is based on the difference between their forward price-to-earnings ratios: 14.90x for IDNA and 19.29x for XBI.
Active M&A pipeline—With overall sector transformation risk declining, the market sees this as a potential driver for further merger and acquisition activity. Companies such as Revolution Medicines (RVMD.US), IDEAYA Biosciences (IDYA.US), Arcus Biosciences (RCUS.US), and Iovance Biotherapeutics (IOVA.US) are being mentioned as potential acquisition targets.
Technical and fundamental signals are resonating—Analyst Mike Zaccardi points out that XBI’s bullish technical momentum is building, including a steadily rising 200-day moving average and strong RSI performance, while the valuation is at what he considers reasonable levels. These two factors are resonating together.
Potential Downside Factors Worth Noting
Macro shock risks remain—Mike Zaccardi also notes that higher financing costs and risks of broader macroeconomic disruptions could negatively impact the industry's M&A deal flow and R&D spending.
Structural volatility in small-cap stocks—XBI has a high beta and small-cap risk characteristics, making the ETF prone to large drawdowns, especially during periods of broad market stress.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Canada signals further interest rate hikes! Meeting minutes: High oil prices increase inflation risk, economic uncertainty will not hinder policy actions
The minutes of the Bank of Canada's October meeting reveal that, despite persistently high international oil prices and significant uncertainties in Canada's economic outlook caused by trade disputes with the United States, policymakers believe these risks do not mean the central bank must pause its actions.
Federal Reserve officials intensively deliver hawkish remarks! Waller calls for a 50 basis point rate hike in December, Bowman warns that AI investment returns may fall short of expectations, potentially triggering a sharp correction in US stocks
Several Federal Reserve officials issued consecutive hawkish signals on Tuesday, stating that inflationary pressures in the United States remain persistent and that monetary policy still needs to be further tightened.
Overnight US Stocks | Fed Rate Hike Expectations Rise, Major Indexes Fall, Nvidia (NVDA.US) Continues to Drop 5.4%
At the close, the Dow Jones Index fell by 156.67 points, down 0.30%, to 52,233.08 points; the S&P 500 Index dropped 28.99 points, down 0.38%, to 7,520.95 points; and the Nasdaq Composite Index declined 187.26 points, down 0.74%, to 25,065.87 points.
CoreWeave (CRWV.US) Q3 revenue surged 168% year-on-year, raised full-year revenue guidance, surged about 5% after hours
Benefiting from the continued growth in demand for AI computing power, CoreWeave's third-quarter revenue increased by 168% year-on-year, surpassing Wall Street expectations, and the company has raised its full-year revenue guidance.
Crypto prices
More
